Skip to main content
Erschienen in: Inflammation 6/2022

08.06.2022 | Original Article

Cannabinoid Analogue WIN 55212–2 Protects Paraquat-Induced Lung Injury and Enhances Macrophage M2 Polarization

verfasst von: Quan He, Wen Zhang, Jinjuan Zhang, Yuanyou Deng

Erschienen in: Inflammation | Ausgabe 6/2022

Einloggen, um Zugang zu erhalten

Abstract

WIN 55212–2 is an endocannabinoids analogue that has been reported to have anti-inflammatory and anti-fibrosis effects on different models. In this study, we investigated the protective effects of WIN 55212–2 on paraquat (PQ)-induced poison on mice especially on lung injury. Mice were administrated with different dose of PQ and thereafter treated with 0.2 mg/kg or 1 mg/kg WIN 55212–2. The survival of mice was recorded during 4 weeks of observation. Twenty-eight days after PQ treatment, the cell population and inflammatory factors IL-6, IL-10, and TNF-α were measured in bronchoalveolar lavage fluid (BALF). Pulmonary fibrosis was evaluated by Masson staining. Our results showed that WIN 55212–2 treatment reduced PQ-induced mortality of mice in a dose dependent manner. It decreased the number of inflammation-associated cells, as well as the level of pro-inflammatory factors in BALF (P < 0.05). WIN 55212–2 increased M2 cells in BALF (P < 0.05), improved the lung histology, reduced fibrosis formation, and decreased TGF-β, α-SMA and PDGFRa expression. The protective effects of WIN 55212–2 on PQ-induced lung injury and fibrosis were associated with an increase inM2 cells and increased expressions of IL-10, CD163, and CD206, suggesting that polarization of M2 macrophages may be involved in WIN 55212–2 protective effects on PQ-induced lung injury.
Literatur
1.
Zurück zum Zitat Dinis-Oliveira, R.J., J.A. Duarte, A. Sanchez-Navarro, F. Remiao, M.L. Bastos, and F. Carvalho. 2008. Paraquat poisonings: Mechanisms of lung toxicity, clinical features, and treatment. Critical reviews in toxicology 38 (1): 13–71.PubMedCrossRef Dinis-Oliveira, R.J., J.A. Duarte, A. Sanchez-Navarro, F. Remiao, M.L. Bastos, and F. Carvalho. 2008. Paraquat poisonings: Mechanisms of lung toxicity, clinical features, and treatment. Critical reviews in toxicology 38 (1): 13–71.PubMedCrossRef
2.
Zurück zum Zitat Elenga, N., C. Merlin, R. Le Guern, R. Kom-Tchameni, Y.M. Ducrot, M. Pradier, B. Ntab, K.A. Dinh-Van, M. Sobesky, D. Mathieu, et al. 2018. Clinical features and prognosis of paraquat poisoning in French Guiana: A review of 62 cases. Medicine (Baltimore) 97 (15): e9621.CrossRef Elenga, N., C. Merlin, R. Le Guern, R. Kom-Tchameni, Y.M. Ducrot, M. Pradier, B. Ntab, K.A. Dinh-Van, M. Sobesky, D. Mathieu, et al. 2018. Clinical features and prognosis of paraquat poisoning in French Guiana: A review of 62 cases. Medicine (Baltimore) 97 (15): e9621.CrossRef
3.
Zurück zum Zitat Xu, L., J. Xu, and Z. Wang. 2014. Molecular mechanisms of paraquat-induced acute lung injury: A current review. Drug and chemical toxicology 37 (2): 130–134.PubMedCrossRef Xu, L., J. Xu, and Z. Wang. 2014. Molecular mechanisms of paraquat-induced acute lung injury: A current review. Drug and chemical toxicology 37 (2): 130–134.PubMedCrossRef
4.
Zurück zum Zitat Smith, L.L. 1982. Young Scientists Award lecture 1981: the identification of an accumulation system for diamines and polyamines into the lung and its relevance to paraquat toxicity. Archives of toxicology Supplement = Archiv fur Toxikologie Supplement 5:1–14. Smith, L.L. 1982. Young Scientists Award lecture 1981: the identification of an accumulation system for diamines and polyamines into the lung and its relevance to paraquat toxicity. Archives of toxicology Supplement = Archiv fur Toxikologie Supplement 5:1–14.
5.
Zurück zum Zitat Balistreri, E., E. Garcia-Gonzalez, E. Selvi, A. Akhmetshina, K. Palumbo, S. Lorenzini, R. Maggio, M. Lucattelli, M. Galeazzi, and J.W. Distler. 2011. The cannabinoid WIN 55, 212–2 abrogates dermal fibrosis in scleroderma bleomycin model. Annals of the rheumatic diseases 70 (4): 695–699.PubMedCrossRef Balistreri, E., E. Garcia-Gonzalez, E. Selvi, A. Akhmetshina, K. Palumbo, S. Lorenzini, R. Maggio, M. Lucattelli, M. Galeazzi, and J.W. Distler. 2011. The cannabinoid WIN 55, 212–2 abrogates dermal fibrosis in scleroderma bleomycin model. Annals of the rheumatic diseases 70 (4): 695–699.PubMedCrossRef
6.
Zurück zum Zitat Hao, M.X., L.S. Jiang, N.Y. Fang, J. Pu, L.H. Hu, L.H. Shen, W. Song, and B. He. 2010. The cannabinoid WIN 55212–2 protects against oxidized LDL-induced inflammatory response in murine macrophages. Journal of Lipid Research 51 (8): 2181–2190.PubMedPubMedCentralCrossRef Hao, M.X., L.S. Jiang, N.Y. Fang, J. Pu, L.H. Hu, L.H. Shen, W. Song, and B. He. 2010. The cannabinoid WIN 55212–2 protects against oxidized LDL-induced inflammatory response in murine macrophages. Journal of Lipid Research 51 (8): 2181–2190.PubMedPubMedCentralCrossRef
7.
Zurück zum Zitat Teixeira-Clerc, F., B. Julien, P. Grenard, J. Tran Van Nhieu, V. Deveaux, L. Li, V. Serriere-Lanneau, C. Ledent, A. Mallat, and S. Lotersztajn. 2006. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nature medicine 12 (6): 671–676. Teixeira-Clerc, F., B. Julien, P. Grenard, J. Tran Van Nhieu, V. Deveaux, L. Li, V. Serriere-Lanneau, C. Ledent, A. Mallat, and S. Lotersztajn. 2006. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nature medicine 12 (6): 671–676.
8.
Zurück zum Zitat Patsenker, E., M. Stoll, G. Millonig, A. Agaimy, T. Wissniowski, V. Schneider, S. Mueller, R. Brenneisen, H.K. Seitz, M. Ocker, et al. 2011. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Molecular medicine 17 (11–12): 1285–1294.PubMedPubMedCentralCrossRef Patsenker, E., M. Stoll, G. Millonig, A. Agaimy, T. Wissniowski, V. Schneider, S. Mueller, R. Brenneisen, H.K. Seitz, M. Ocker, et al. 2011. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Molecular medicine 17 (11–12): 1285–1294.PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Trebicka, J., I. Racz, S.V. Siegmund, E. Cara, M. Granzow, R. Schierwagen, S. Klein, A. Wojtalla, M. Hennenberg, S. Huss, et al. 2011. Role of cannabinoid receptors in alcoholic hepatic injury: Steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver international : Official journal of the International Association for the Study of the Liver 31 (6): 860–870.CrossRef Trebicka, J., I. Racz, S.V. Siegmund, E. Cara, M. Granzow, R. Schierwagen, S. Klein, A. Wojtalla, M. Hennenberg, S. Huss, et al. 2011. Role of cannabinoid receptors in alcoholic hepatic injury: Steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts. Liver international : Official journal of the International Association for the Study of the Liver 31 (6): 860–870.CrossRef
10.
Zurück zum Zitat Cinar, R., M.R. Iyer, Z. Liu, Z. Cao, T. Jourdan, K. Erdelyi, G. Godlewski, G. Szanda, J. Liu, and J.K. Park, et al. 2016. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI insight 1(11). Cinar, R., M.R. Iyer, Z. Liu, Z. Cao, T. Jourdan, K. Erdelyi, G. Godlewski, G. Szanda, J. Liu, and J.K. Park, et al. 2016. Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI insight 1(11).
11.
Zurück zum Zitat Lin, C.L., Y.C. Hsu, P.H. Lee, C.C. Lei, J.Y. Wang, Y.T. Huang, S.Y. Wang, and F.S. Wang. 2014. Cannabinoid receptor 1 disturbance of PPARgamma2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli. Journal of molecular medicine 92 (7): 779–792.PubMedCrossRef Lin, C.L., Y.C. Hsu, P.H. Lee, C.C. Lei, J.Y. Wang, Y.T. Huang, S.Y. Wang, and F.S. Wang. 2014. Cannabinoid receptor 1 disturbance of PPARgamma2 augments hyperglycemia induction of mesangial inflammation and fibrosis in renal glomeruli. Journal of molecular medicine 92 (7): 779–792.PubMedCrossRef
12.
Zurück zum Zitat Lecru, L., C. Desterke, S. Grassin-Delyle, C. Chatziantoniou, S. Vandermeersch, A. Devocelle, A. Vernochet, N. Ivanovski, C. Ledent, S. Ferlicot, et al. 2015. Cannabinoid receptor 1 is a major mediator of renal fibrosis. Kidney international 88 (1): 72–84.PubMedCrossRef Lecru, L., C. Desterke, S. Grassin-Delyle, C. Chatziantoniou, S. Vandermeersch, A. Devocelle, A. Vernochet, N. Ivanovski, C. Ledent, S. Ferlicot, et al. 2015. Cannabinoid receptor 1 is a major mediator of renal fibrosis. Kidney international 88 (1): 72–84.PubMedCrossRef
13.
Zurück zum Zitat Slavic, S., D. Lauer, M. Sommerfeld, U.R. Kemnitz, A. Grzesiak, M. Trappiel, C. Thone-Reineke, J. Baulmann, L. Paulis, K. Kappert, et al. 2013. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of molecular medicine 91 (7): 811–823.PubMedCrossRef Slavic, S., D. Lauer, M. Sommerfeld, U.R. Kemnitz, A. Grzesiak, M. Trappiel, C. Thone-Reineke, J. Baulmann, L. Paulis, K. Kappert, et al. 2013. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of molecular medicine 91 (7): 811–823.PubMedCrossRef
14.
Zurück zum Zitat Lazzerini, P.E., M. Natale, E. Gianchecchi, P.L. Capecchi, C. Montilli, S. Zimbone, M. Castrichini, E. Balistreri, G. Ricci, E. Selvi, et al. 2012. Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. Journal of molecular medicine 90 (3): 331–342.PubMedCrossRef Lazzerini, P.E., M. Natale, E. Gianchecchi, P.L. Capecchi, C. Montilli, S. Zimbone, M. Castrichini, E. Balistreri, G. Ricci, E. Selvi, et al. 2012. Adenosine A2A receptor activation stimulates collagen production in sclerodermic dermal fibroblasts either directly and through a cross-talk with the cannabinoid system. Journal of molecular medicine 90 (3): 331–342.PubMedCrossRef
15.
Zurück zum Zitat Sipe, J.C., N. Arbour, A. Gerber, and E. Beutler. 2005. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: Possible risk for autoimmune disorders. Journal of leukocyte biology 78 (1): 231–238.PubMedCrossRef Sipe, J.C., N. Arbour, A. Gerber, and E. Beutler. 2005. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: Possible risk for autoimmune disorders. Journal of leukocyte biology 78 (1): 231–238.PubMedCrossRef
16.
Zurück zum Zitat Castaneda, J.T., A. Harui, and M.D. Roth. 2017. Regulation of cell surface CB2 receptor during human B cell activation and differentiation. Journal of neuroimmune pharmacology : The official journal of the Society on NeuroImmune Pharmacology 12 (3): 544–554.CrossRef Castaneda, J.T., A. Harui, and M.D. Roth. 2017. Regulation of cell surface CB2 receptor during human B cell activation and differentiation. Journal of neuroimmune pharmacology : The official journal of the Society on NeuroImmune Pharmacology 12 (3): 544–554.CrossRef
17.
Zurück zum Zitat Aragão, L.G.H.S., J.T. Oliveira, J.R. Temerozo, M.A. Mendes, J.A. Salerno, C.S.G. Pedrosa, T. Puig-Pijuan, C.P. Veríssimo, I.M. Ornelas, T. Torquato, et al. 2021. WIN 55212–2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2. PeerJ 9: e12262–e12262.PubMedPubMedCentralCrossRef Aragão, L.G.H.S., J.T. Oliveira, J.R. Temerozo, M.A. Mendes, J.A. Salerno, C.S.G. Pedrosa, T. Puig-Pijuan, C.P. Veríssimo, I.M. Ornelas, T. Torquato, et al. 2021. WIN 55212–2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2. PeerJ 9: e12262–e12262.PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Devane, W.A., F.A. Dysarz 3rd., M.R. Johnson, L.S. Melvin, and A.C. Howlett. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34 (5): 605–613.PubMed Devane, W.A., F.A. Dysarz 3rd., M.R. Johnson, L.S. Melvin, and A.C. Howlett. 1988. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology 34 (5): 605–613.PubMed
19.
Zurück zum Zitat Munro, S., K.L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (6441): 61–65.PubMedCrossRef Munro, S., K.L. Thomas, and M. Abu-Shaar. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (6441): 61–65.PubMedCrossRef
20.
Zurück zum Zitat Wang, B., A. Kovalchuk, D. Li, R. Rodriguez-Juarez, Y. Ilnytskyy, I. Kovalchuk, and O. Kovalchuk. 2020. In search of preventive strategies: Novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY) 12 (22): 22425–22444. Wang, B., A. Kovalchuk, D. Li, R. Rodriguez-Juarez, Y. Ilnytskyy, I. Kovalchuk, and O. Kovalchuk. 2020. In search of preventive strategies: Novel high-CBD Cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Aging (Albany NY) 12 (22): 22425–22444.
21.
Zurück zum Zitat Tveden-Nyborg, P., T.K. Bergmann, and J. Lykkesfeldt. 2018. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. Basic & clinical pharmacology & toxicology 123 (3): 233–235.CrossRef Tveden-Nyborg, P., T.K. Bergmann, and J. Lykkesfeldt. 2018. Basic & Clinical Pharmacology & Toxicology Policy for Experimental and Clinical studies. Basic & clinical pharmacology & toxicology 123 (3): 233–235.CrossRef
22.
Zurück zum Zitat Hellenbrand, D.J., K.A. Reichl, B.J. Travis, M.E. Filipp, A.S. Khalil, D.J. Pulito, A.V. Gavigan, E.R. Maginot, M.T. Arnold, A.G. Adler, et al. 2019. Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury. Journal of neuroinflammation 16 (1): 93.PubMedPubMedCentralCrossRef Hellenbrand, D.J., K.A. Reichl, B.J. Travis, M.E. Filipp, A.S. Khalil, D.J. Pulito, A.V. Gavigan, E.R. Maginot, M.T. Arnold, A.G. Adler, et al. 2019. Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury. Journal of neuroinflammation 16 (1): 93.PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Balasingam, V., and V.W. Yong. 1996. Attenuation of astroglial reactivity by interleukin-10. The Journal of neuroscience : The official journal of the Society for Neuroscience 16 (9): 2945–2955.CrossRef Balasingam, V., and V.W. Yong. 1996. Attenuation of astroglial reactivity by interleukin-10. The Journal of neuroscience : The official journal of the Society for Neuroscience 16 (9): 2945–2955.CrossRef
24.
Zurück zum Zitat Bustos, M.L., L. Huleihel, E.M. Meyer, A.D. Donnenberg, V.S. Donnenberg, J.D. Sciurba, L. Mroz, B.J. McVerry, B.M. Ellis, N. Kaminski, et al. 2013. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem cells translational medicine 2 (11): 884–895.PubMedPubMedCentralCrossRef Bustos, M.L., L. Huleihel, E.M. Meyer, A.D. Donnenberg, V.S. Donnenberg, J.D. Sciurba, L. Mroz, B.J. McVerry, B.M. Ellis, N. Kaminski, et al. 2013. Activation of human mesenchymal stem cells impacts their therapeutic abilities in lung injury by increasing interleukin (IL)-10 and IL-1RN levels. Stem cells translational medicine 2 (11): 884–895.PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Hoegl, S., K.A. Boost, H. Czerwonka, A. Dolfen, P. Scheiermann, H. Muhl, B. Zwissler, and C. Hofstetter. 2009. Inhaled IL-10 reduces biotrauma and mortality in a model of ventilator-induced lung injury. Respiratory medicine 103 (3): 463–470.PubMedCrossRef Hoegl, S., K.A. Boost, H. Czerwonka, A. Dolfen, P. Scheiermann, H. Muhl, B. Zwissler, and C. Hofstetter. 2009. Inhaled IL-10 reduces biotrauma and mortality in a model of ventilator-induced lung injury. Respiratory medicine 103 (3): 463–470.PubMedCrossRef
26.
Zurück zum Zitat Xu, S., M. Xu, G.G. Li, C. Wang, H. Song, and J. Bai. 2016. Early recruitment of IL-10-producing B cells into alveoli improved the resolution of acute lung injury. Cellular physiology and biochemistry : International journal of experimental cellular physiology, biochemistry, and pharmacology 38 (5): 1752–1760.CrossRef Xu, S., M. Xu, G.G. Li, C. Wang, H. Song, and J. Bai. 2016. Early recruitment of IL-10-producing B cells into alveoli improved the resolution of acute lung injury. Cellular physiology and biochemistry : International journal of experimental cellular physiology, biochemistry, and pharmacology 38 (5): 1752–1760.CrossRef
27.
Zurück zum Zitat Marquart, S., P. Zerr, A. Akhmetshina, K. Palumbo, N. Reich, M. Tomcik, A. Horn, C. Dees, M. Engel, J. Zwerina, et al. 2010. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and rheumatism 62 (11): 3467–3476.PubMedCrossRef Marquart, S., P. Zerr, A. Akhmetshina, K. Palumbo, N. Reich, M. Tomcik, A. Horn, C. Dees, M. Engel, J. Zwerina, et al. 2010. Inactivation of the cannabinoid receptor CB1 prevents leukocyte infiltration and experimental fibrosis. Arthritis and rheumatism 62 (11): 3467–3476.PubMedCrossRef
28.
Zurück zum Zitat Servettaz, A., N. Kavian, C. Nicco, V. Deveaux, C. Chereau, A. Wang, A. Zimmer, S. Lotersztajn, B. Weill, and F. Batteux. 2010. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. The American journal of pathology 177 (1): 187–196.PubMedPubMedCentralCrossRef Servettaz, A., N. Kavian, C. Nicco, V. Deveaux, C. Chereau, A. Wang, A. Zimmer, S. Lotersztajn, B. Weill, and F. Batteux. 2010. Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. The American journal of pathology 177 (1): 187–196.PubMedPubMedCentralCrossRef
29.
Zurück zum Zitat Cinar, R., B.R. Gochuico, M.R. Iyer, T. Jourdan, T. Yokoyama, J.K. Park, N.J. Coffey, H. Pri-Chen, G. Szanda, Z. Liu, et al. 2017. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI insight 2(8). Cinar, R., B.R. Gochuico, M.R. Iyer, T. Jourdan, T. Yokoyama, J.K. Park, N.J. Coffey, H. Pri-Chen, G. Szanda, Z. Liu, et al. 2017. Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI insight 2(8).
30.
Zurück zum Zitat Bronova, I., B. Smith, B. Aydogan, R.R. Weichselbaum, K. Vemuri, K. Erdelyi, A. Makriyannis, P. Pacher, and E.V. Berdyshev. 2015. Protection from radiation-induced pulmonary fibrosis by peripheral targeting of cannabinoid receptor-1. American journal of respiratory cell and molecular biology 53 (4): 555–562.PubMedPubMedCentralCrossRef Bronova, I., B. Smith, B. Aydogan, R.R. Weichselbaum, K. Vemuri, K. Erdelyi, A. Makriyannis, P. Pacher, and E.V. Berdyshev. 2015. Protection from radiation-induced pulmonary fibrosis by peripheral targeting of cannabinoid receptor-1. American journal of respiratory cell and molecular biology 53 (4): 555–562.PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Reczek, C.R., K. Birsoy, H. Kong, I. Martínez-Reyes, T. Wang, P. Gao, D.M. Sabatini, and N.S. Chandel. 2017. A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nature Chemical Biology 13 (12): 1274–1279.PubMedPubMedCentralCrossRef Reczek, C.R., K. Birsoy, H. Kong, I. Martínez-Reyes, T. Wang, P. Gao, D.M. Sabatini, and N.S. Chandel. 2017. A CRISPR screen identifies a pathway required for paraquat-induced cell death. Nature Chemical Biology 13 (12): 1274–1279.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Zhang, Z.D., Y.J. Yang, X.W. Liu, Z. Qin, S.H. Li, and J.Y. Li. 2021. Aspirin eugenol ester ameliorates paraquat-induced oxidative damage through ROS/p38-MAPK-mediated mitochondrial apoptosis pathway. Toxicology 453: 152721.PubMedCrossRef Zhang, Z.D., Y.J. Yang, X.W. Liu, Z. Qin, S.H. Li, and J.Y. Li. 2021. Aspirin eugenol ester ameliorates paraquat-induced oxidative damage through ROS/p38-MAPK-mediated mitochondrial apoptosis pathway. Toxicology 453: 152721.PubMedCrossRef
33.
Zurück zum Zitat Hu, X., H. Shen, Y. Wang, and M. Zhao. 2017. Liver X receptor agonist TO901317 attenuates paraquat-induced acute lung injury through inhibition of NF-κB and JNK/p38 MAPK signal pathways. BioMed Research International 2017: 4652695.PubMedPubMedCentralCrossRef Hu, X., H. Shen, Y. Wang, and M. Zhao. 2017. Liver X receptor agonist TO901317 attenuates paraquat-induced acute lung injury through inhibition of NF-κB and JNK/p38 MAPK signal pathways. BioMed Research International 2017: 4652695.PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Pei, Y.H., X.M. Cai, J. Chen, B.D. Sun, Z.R. Sun, X. Wang, and X.M. Qian. 2014. The role of p38 MAPK in acute paraquat-induced lung injury in rats. Inhalation Toxicology 26 (14): 880–884.PubMedCrossRef Pei, Y.H., X.M. Cai, J. Chen, B.D. Sun, Z.R. Sun, X. Wang, and X.M. Qian. 2014. The role of p38 MAPK in acute paraquat-induced lung injury in rats. Inhalation Toxicology 26 (14): 880–884.PubMedCrossRef
35.
Zurück zum Zitat Kim, S.H., S.J. Won, X.O. Mao, K. Jin, and D.A. Greenberg. 2005. Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. Journal of Pharmacology and Experimental Therapeutics 313 (1): 88–94.PubMedCrossRef Kim, S.H., S.J. Won, X.O. Mao, K. Jin, and D.A. Greenberg. 2005. Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. Journal of Pharmacology and Experimental Therapeutics 313 (1): 88–94.PubMedCrossRef
36.
Zurück zum Zitat Bátkai, S., D. Osei-Hyiaman, H. Pan, O. El-Assal, M. Rajesh, P. Mukhopadhyay, F. Hong, J. Harvey-White, A. Jafri, G. Haskó, et al. 2007. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. The FASEB Journal 21 (8): 1788–1800.PubMedCrossRef Bátkai, S., D. Osei-Hyiaman, H. Pan, O. El-Assal, M. Rajesh, P. Mukhopadhyay, F. Hong, J. Harvey-White, A. Jafri, G. Haskó, et al. 2007. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. The FASEB Journal 21 (8): 1788–1800.PubMedCrossRef
37.
Zurück zum Zitat Di Filippo, C., F. Rossi, S. Rossi, and M. D’Amico. 2004. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: Involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology 75 (3): 453–459.PubMedCrossRef Di Filippo, C., F. Rossi, S. Rossi, and M. D’Amico. 2004. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: Involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology 75 (3): 453–459.PubMedCrossRef
38.
Zurück zum Zitat Garberg, H.T., M.U. Huun, J. Escobar, J. Martinez-Orgado, E.M. Løberg, R. Solberg, and O. Didrik Saugstad. 2016. Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets. Pediatric Research 80 (5): 710–718.PubMedCrossRef Garberg, H.T., M.U. Huun, J. Escobar, J. Martinez-Orgado, E.M. Løberg, R. Solberg, and O. Didrik Saugstad. 2016. Short-term effects of cannabidiol after global hypoxia-ischemia in newborn piglets. Pediatric Research 80 (5): 710–718.PubMedCrossRef
39.
Zurück zum Zitat Alonso-Alconada, D., F.J. Álvarez, F. Goñi-de-Cerio, E. Hilario, and A. Álvarez. 2020. Cannabinoid-mediated modulation of oxidative stress and early inflammatory response after hypoxia-ischemia. International Journal of Molecular Sciences 21(4). Alonso-Alconada, D., F.J. Álvarez, F. Goñi-de-Cerio, E. Hilario, and A. Álvarez. 2020. Cannabinoid-mediated modulation of oxidative stress and early inflammatory response after hypoxia-ischemia. International Journal of Molecular Sciences 21(4).
40.
41.
Zurück zum Zitat Cheng, P., S. Li, and H. Chen. 2021. Macrophages in lung injury, repair, and fibrosis. Cells 10(2). Cheng, P., S. Li, and H. Chen. 2021. Macrophages in lung injury, repair, and fibrosis. Cells 10(2).
42.
Zurück zum Zitat Schülke, S. 2018. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Frontiers in Immunology 9: 455.PubMedPubMedCentralCrossRef Schülke, S. 2018. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Frontiers in Immunology 9: 455.PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Lamkhioued, B., A.S. Gounni, D. Aldebert, E. Delaporte, L. Prin, A. Capron, and M. Capron. 1996. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Annals of the New York Academy of Sciences 796: 203–208.PubMedCrossRef Lamkhioued, B., A.S. Gounni, D. Aldebert, E. Delaporte, L. Prin, A. Capron, and M. Capron. 1996. Synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Annals of the New York Academy of Sciences 796: 203–208.PubMedCrossRef
44.
Zurück zum Zitat Li, L., H. Si, S.W. Wu, J.O. Mendez, D. Zarlenga, W. Tuo, and Z. Xiao. 2019. Characterization of IL-10-producing neutrophils in cattle infected with Ostertagia ostertagi. Science and Reports 9 (1): 20292.CrossRef Li, L., H. Si, S.W. Wu, J.O. Mendez, D. Zarlenga, W. Tuo, and Z. Xiao. 2019. Characterization of IL-10-producing neutrophils in cattle infected with Ostertagia ostertagi. Science and Reports 9 (1): 20292.CrossRef
45.
Zurück zum Zitat Cerqueira, C., B. Manfroi, and S. Fillatreau. 2019. IL-10-producing regulatory B cells and plasmocytes: Molecular mechanisms and disease relevance. Seminars in Immunology 44: 101323.PubMedCrossRef Cerqueira, C., B. Manfroi, and S. Fillatreau. 2019. IL-10-producing regulatory B cells and plasmocytes: Molecular mechanisms and disease relevance. Seminars in Immunology 44: 101323.PubMedCrossRef
46.
Zurück zum Zitat Bedke, T., F. Muscate, S. Soukou, N. Gagliani, and S. Huber. 2019. Title: IL-10-producing T cells and their dual functions. Seminars in Immunology 44: 101335.PubMedCrossRef Bedke, T., F. Muscate, S. Soukou, N. Gagliani, and S. Huber. 2019. Title: IL-10-producing T cells and their dual functions. Seminars in Immunology 44: 101335.PubMedCrossRef
47.
Zurück zum Zitat Angelina, A., M. Pérez-Diego, J. López-Abente, B. Rückert, I. Nombela, M. Akdis, M. Martín-Fontecha, C. Akdis, and O. Palomares. 2022. Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming. Mucosal Immunology 15 (1): 96–108.PubMedCrossRef Angelina, A., M. Pérez-Diego, J. López-Abente, B. Rückert, I. Nombela, M. Akdis, M. Martín-Fontecha, C. Akdis, and O. Palomares. 2022. Cannabinoids induce functional Tregs by promoting tolerogenic DCs via autophagy and metabolic reprograming. Mucosal Immunology 15 (1): 96–108.PubMedCrossRef
Metadaten
Titel
Cannabinoid Analogue WIN 55212–2 Protects Paraquat-Induced Lung Injury and Enhances Macrophage M2 Polarization
verfasst von
Quan He
Wen Zhang
Jinjuan Zhang
Yuanyou Deng
Publikationsdatum
08.06.2022
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 6/2022
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-022-01688-z

Weitere Artikel der Ausgabe 6/2022

Inflammation 6/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.